BHVN Quote, Financials, Valuation and Earnings

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of 38.89%. Biohaven Ltd.'s return on equity of -349.4% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Biohaven Ltd. has a consensus price target of $19.80, signalling upside risk potential of 88.57%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that Biohaven Ltd. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Biohaven Ltd. is more attractive than Regeneron Pharmaceuticals, Inc..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Biohaven Ltd.'s net income of -$173.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of 39.4%. Biohaven Ltd.'s return on equity of -349.4% beat Soleno Therapeutics, Inc.'s return on equity of -26.56%.

Biohaven Ltd. has a consensus price target of $19.80, signalling upside risk potential of 88.57%. On the other hand Soleno Therapeutics, Inc. has an analysts' consensus of $113.54 which suggests that it could grow by 131.05%. Given that Soleno Therapeutics, Inc. has higher upside potential than Biohaven Ltd., analysts believe Soleno Therapeutics, Inc. is more attractive than Biohaven Ltd..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics, Inc. has a beta of -3.150, suggesting its less volatile than the S&P 500 by 415.022%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Soleno Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Soleno Therapeutics, Inc. quarterly revenues of $66M. Biohaven Ltd.'s net income of -$173.4M is lower than Soleno Therapeutics, Inc.'s net income of $26M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Soleno Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 24.34x for Soleno Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of -86.59%. Biohaven Ltd.'s return on equity of -349.4% beat Stereotaxis, Inc.'s return on equity of -218.3%.

Biohaven Ltd. has a consensus price target of $19.80, signalling upside risk potential of 88.57%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 72.84%. Given that Biohaven Ltd. has higher upside potential than Stereotaxis, Inc., analysts believe Biohaven Ltd. is more attractive than Stereotaxis, Inc..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Stereotaxis, Inc. quarterly revenues of $7.5M. Biohaven Ltd.'s net income of -$173.4M is lower than Stereotaxis, Inc.'s net income of -$6.5M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 7.16x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of -- compared to Biohaven Ltd.'s net margin of -28.7%. Biohaven Ltd.'s return on equity of -349.4% beat Xencor, Inc.'s return on equity of -20.07%.

Biohaven Ltd. has a consensus price target of $19.80, signalling upside risk potential of 88.57%. On the other hand Xencor, Inc. has an analysts' consensus of $28.25 which suggests that it could grow by 82.85%. Given that Biohaven Ltd. has higher upside potential than Xencor, Inc., analysts believe Biohaven Ltd. is more attractive than Xencor, Inc..

Biohaven Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.

Biohaven Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biohaven Ltd. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

Biohaven Ltd. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. Biohaven Ltd.'s net income of -$173.4M is lower than Xencor, Inc.'s net income of -$6M. Notably, Biohaven Ltd.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biohaven Ltd. is -- versus 7.60x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.